Search

Displaying results 8951 - 8960 of 10000 in total
  1. Drug

    Lemuteporfin

    go.drugbank.com/drugs/DB04980
    Investigational

    Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

  2. Drug

    Macozinone

    go.drugbank.com/drugs/DB14821
    Investigational

    Macozinone is under investigation in clinical trial NCT03036163 (Phase 1 Study of PBTZ169).

  3. Drug

    JQ1

    go.drugbank.com/drugs/DB17021
    Experimental

    First-in-class potent and selective inhibitor of the BRD4 signaling pathway.[A252967]

  4. Drug

    NKX101

    go.drugbank.com/drugs/DB18131
    Investigational

    NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.

    Synonyms: a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15
  5. Drug

    MSX-122

    go.drugbank.com/drugs/DB12715
    Investigational

    MSX-122 has been used in trials studying the treatment of Solid Tumors.

  6. Drug

    Alvircept sudotox

    go.drugbank.com/drugs/DB12786
    Investigational

    Alvircept Sudotox has been used in trials studying the treatment of HIV Infections.

  7. Drug

    MK-7622

    go.drugbank.com/drugs/DB12897
    Investigational

    MK-7622 has been used in trials studying the treatment of Alzheimer's Disease.

  8. Drug

    TT-301

    go.drugbank.com/drugs/DB12899
    Investigational

    TT301 has been used in trials studying the treatment of Traumatic Brain Injury.

  9. Drug

    XL-888

    go.drugbank.com/drugs/DB12981
    Investigational

    XL888 has been used in trials studying the treatment of Cancer and Melanoma.

  10. Drug

    LY-518674

    go.drugbank.com/drugs/DB12988
    Investigational

    LY518674 has been used in trials studying the treatment of Metabolic Syndrome X.